Blockade of costimulatory pathways of T-cell activation: the solution to acute and chronic rejection?
Understanding of how antigen-specific signals and costimulatory molecules are involved in T-cell activation has resulted in new strategies to interfere with allograft rejection. The present review focuses on the role of two receptor-ligand pairs: CD28 and cytotoxic T lymphocyte associated antigen-4, which interact with the B7 ligands (CD80, CD86); and CD40, which interacts with the CD40L (CD154). On the basis of the extensive tissue distribution of CD40, it is likely that the CD40/CD40L system plays a much broader role.
van Kooten
C
C
Department of Nephrology, Leiden University Medical Center, The Netherlands. Kooten@mail.Medfac.LeidenUniv.nl
D000208:Acute Disease; D018106:CD28 Antigens / Q000276:immunology; D019013:CD40 Antigens / Q000276:immunology; D002908:Chronic Disease; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000276:immunology
D018106:CD28 Antigens; D019013:CD40 Antigens; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7